The menopause, hormone replacement therapy and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 83, Issue 1-5, 2002, Pages 123-132

  Marsden, Jo ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Hormone replacement therapy; Menopause

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL STIMULATION; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; PHENOTYPE; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT CONTRAINDICATION; ADOLESCENT; ADULT; AGE; AGED; BLOOD; BREAST TUMOR; FEMALE; MIDDLE AGED; REVIEW; RISK; TIME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PHENOTYPE; RISK; RISK FACTORS; TIME FACTORS;

EID: 0037981360     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00258-3     Document Type: Conference Paper

References (75)

1. Collaborative Group on Hormonal Factors for Breast Cancer, Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies, Lancet 350 (1997) 1047-1060.
2. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360:2002;942-944.
3. Pike M.C., Peters R.K., Cozen W., Probst-Hensch N.M., Felix J.C., Wan P.C., Mack T.M. Estrogen-progestin replacement therapy and endometrial cancer. J. Natl. Cancer Inst. 89:1997;1110-1116.
4. M.I. Whitehead, V. Godfree, Types of HRT available, in: M.I. Whitehead, V. Godfree (Eds.), HRT: Your Questions Answered, 1st ed., Churchill Livingstone, Edingburgh, 1992, pp. 93-122.
5. Gangar K.F., Cust M., Whitehead M.I. Prolonged endometrial stimulation associated with oestradiol implants. BMJ. 299:1989;601-602.
6. Carter A.C., Sedransk N., Kelley R.M., Ansfield F.J., Ravdin R.G., Talley R.W., Potter N.R. Diethylstilbestrol: recommended doasages for different categories of breast cancer patients. JAMA. 237:1977;2079-2085.
7. Palshof T., Mouridsen H.T., Daehnfeldt J.L. Adjuvant endocrine therapy of breast cancer - a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen Breast Cancer Trials. Recent Results Cancer Res. 71:1980;185-189.
8. Beex L., Pieters G., Smals A., Koenders A., Benraad T., Kloppenborg P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat. Rep. 65:1981;179-185.
9. Peethambaram P.P., Ingle J.N., Suman V.J., Hartmann L.C., Loprinzi C.L. Randomised trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer: an updated analysis. Breast Cancer Res. Treat. 54:1999;117-122.
10. Wren B.G. Hormonal replacement therapy and breast cancer. Eur. J. Menopause. 2:1995;13-21.
11. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas. 12:1990;171-197.
12. Birrell S.N., Bentel J.M., Hickey T.E., Ricciardelli C.R., Weger M.A., Horsfall D.J., Tilley W.D. Androgenes induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 52:1995;459-467.
13. The Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies, J. Natl. Cancer Inst. 94 (2002) 606-616.
14. Cummings S.R., Duong T., Kenyon E., Cauley J.A., Whitehead M.I., Krueger K.A. Multiple Outcomes of Raloxifene Evaluation (MORE) Trial, serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 287:2002;216-220.
15. Key T.J.A., Pike M.C. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol. 24:1988;29-43.
16. Anderson T.J., Ferguson D.J., Raab G.M. Cell turn-over in the 'resting' human breast: influence of parity, contraceptive pill, age and laterality. Br. J. Cancer. 46:1982;376-382.
17. Badwe R.A., Wang W.Y., Gregory W.M., Fentiman I.S., Chaudary M.A., Rubens R.D. Timing of surgery during the menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 337:1991;1261-1264.
18. Mohr M.E., Wang D.Y., Gregory W.M., Richards M.A., Fentiman I.S. Serum progesterone and prognosis in operable breast cancer. Br. J. Cancer. 73:1996;1552-1553.
19. G.A. Colditz, B. Rosner, Nurses' Health Study Research Group, Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone, Am. J. Epidemiol. 147 (Suppl.) (1998) 64S.
20. Persson, E. Weiderpass, R. Bergstrom, C. Schairer, Risks of breast cancer and endometrial cancer after estrogen and estrogen-progestin replacement therapy, Cancer Causes Contr. 10 (1999) 253-260.
21. Magnusson C., Baron J.A., Correia N., Bergström R., Adami H.O., Persson I. Breast cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy. Int. J. Cancer. 81:1999;339-344.
22. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
23. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy and breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332.
24. Armstrong B.K. Oestrogen therapy after the menopause: boon or bane? Med. J. Aust. 148:1988;213-214.
25. Dupont W.D., Page D.L. Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 151:1991;67-72.
26. Steinberg K.K., Thacker S.B., Smith J.S., Stroup D.F., Zack M.M., Flanders W.D., Berkelman R.L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 265:1991;1985-1990.
27. Grady D., Ernster V. Invited commentary: does hormone replacement therapy cause breast cancer? Am. J. Epidemol. 143:1991;1396-1400.
28. Sillero-Arenas M., Delgado-Rodriguez M., Rodigues-Canteras R., Bueno-Cavanillas A., Galvez Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet. Gynaecol. 79:1992;286-294.
29. Colditz G.A., Egan K.M., Stampfer M.J. Hormone replacement therapy and risk of breast cancer: results from epidemiological studies. Am. J. Obs. Gynaecol. 168:1993;1473-1480.
30. S. Hulley, D. Grady, T. Bush, C. Furgberg, D. Herrington, B. Riggs, E. Vittinghoff for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group, Randomised trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, JAMA 280 (1998) 605-613.
31. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women, JAMA 288 (2002) 321-333.
32. Vickers M. The MRC long-term randomised control trial of hormone replacement therapy: background. J. Br. Menopause Soc. 2:1996;9-13.
33. MRC Media Release, MRC stops study of long-term use of HRT. Available from http://www.mrc.ac.uk (reference MRC/51/02).
34. Nachtigall M.J., Smilen S.W., Nacthigall R.D., Nactigall R.H., Nachtigall L.E. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet. Gynaecol. 80:1992;827-830.
35. Høibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrøm E., Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomised, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis Haemostasis. 84:2000;961-967.
36. Ursin G., Tseng C., Paganini-Hill A., Enger S., Wan P.C., Formenti S., Pike M.C., Ross R.K. Does hormone replacement therapy interact with known factors to increase risk of breast cancer? J. Clin. Oncol. 20:2002;699-706.
37. Byrne C., Schairer C., Wolfe J., Parekh N., Salane M., Brinton L.A., Hoover R., Hale R. Mammographic features and breast cancer risk: effects with time. J. Natl. Cancer Inst. 87:1995;1622-1629.
38. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84:1999;4559-4565.
39. G.A. Greendale, B.A. Reboussin, A. Sie, R. Singh, L.K. Olson, O. Gatewood, L.W. Bassett, C. Wasilaukas, T. Bush, E. Barrett-Connor, Postmenopausal estrogen/progestin interventions (PEPI) investigators, Effects of estrogen and estrogen-progestin on mammographic parenchymal density, Ann. Intern. Med. 130 (1999) 262-269.
40. Freedman M., San Martin J., O'Gorman J., Eckert S., Lippman M.E., Lo S.B., Walls E.L., Zeng J. Digitalised mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen or placebo. J. Natl. Cancer Inst. 93:2001;51-56.
41. Ursin G., Parisky Y.R., Pike M.C., Spicer D.V. Mammographic density changes during the menstrual cycle. Cancer Epidem. Biom. Prev. 10:2001;141-142.
42. Rosenberg R.D., Hunt W.C., Williamson M.R., Gilliland F.D., Wiest P.W., Kelsey C.A., Key C.R., Linver M.N. Effects of age, breast density, ethnicity and estrogen replacement therapy on screening mammographic sensitivity and cancer stage as diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology. 209:1998;511-518.
43. Gapstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favourable histology. JAMA. 281:1999;2091-2097.
44. Diab S.G., Clark G.M., Osborne C.K., Libby A., Allred D.C., Elledge R.M. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J. Clin. Oncol. 17:1999;1442-1448.
45. Adeyinka, F. Mertens, I. Idvall, L. Bondeson, C. Ingvar, S. Heim, F. Mitelman, N. Pandis, Cytogenetic findings in invasive breast carcinomas with prognostically favourable histology: a less complex karyotypic pattern? Int. J. Cancer 79 (1998) 361-364.
46. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials, Lancet 351 (1998) 1451-1467.
47. Early Breast Cancer Trialists' Collaborative Group, Ovarian ablation in early breast cancer: overview of the randomised trials, Lancet 348 (1996) 1189-1196.
48. B. Fisher, J.P. Constatino, D.I. Wickerham, C.K. Redmond, M. Kavanah, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, N. Wolmark, Other National Surgical Adjuvant Breast and Bowel Project Investigators, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J. Natl. Cancer Inst. 90 (1998) 1371-1388.
49. Li C.I., Weiss N.S., Stanford J.L., Darling J.R. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 88:2000;2570-2577.
50. Chen C., Weiss N.S., Newcomb P., Barlow W., White E. Hormone replacement therapy in relation to breast cancer. JAMA. 287:2002;734-741.
51. Fabian C.J., Kimler B.F., McKittrick R., Park C.H., Lin F., Krishnan L., Jewell W.R., Osborne C.K., Martino S., Hutchins L.F. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancer - a Southwest Oncology Group Study. Cancer Res. 54:1994;5357-5362.
52. Dao T.L., Sinha D.K., Memto T., Patel J. Effect of oestrogen and progesterone on cellular replication of human breast tumours. Cancer Res. 42:1982;359-362.
53. Cobleigh M.A., Norlock F.E., Oleske D.M., Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA. 281:1999;1528-1530.
54. U. Veronesi, P. Maisonneuve, V. Sacchini, N. Rotmensz, P. Boyle, Italian Tamoxifen Study Group, Tamoxifen for breast cancer among hysterectomised women, Lancet 359 (2002) 1122-1123.
55. Guerrieri-Gonzaga A., Galli A., Rotmensz N., Decensi A. The Italian breast cancer prevention trial with tamoxifen findings and perspectives. Ann. N.Y. Acad. Sci. 949:2001;113-122.
56. Peto R., Boreham J., Clarke M., Davies C., Beral V. UK and USA breast cancer deaths down 25% in years 2000 at ages 20-69. Lancet. 355:2001;1822.
57. Nanda K., Bastian L.A., Schultz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am. J. Obstet. Gynacol. 186:2002;325-334.
58. Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J. Med. Screen. 8:2001;29-35.
59. Blanks R.G., Moss S.M., Patnick J. Results from the UK NHS breast screening programme 1994-1999. J. Med. Screen. 7:2000;195-198.
60. Harvey J.A., Pinkerton J.V., Herman C.R. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J. Natl. Cancer Inst. 89:1997;1623-1625.
61. Kavanagh A.M., Mitchell H., Giles G.G. Hormone replacement therapy and accuracy of mammographic screening. Lancet. 355:2000;270-274.
62. Stallard S., Litherland J.C., Cordiner C.M., Dobson H.M., George W.D., Mallon E.A., Hole D. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ. 320:2000;348-349.
63. Chlebowski R.T., Aiello E., McTiernan A. Weight loss in breast cancer patient management. J. Clin. Oncol. 20:2002;1128-1143.
64. Lønning P.E., Helle S.I., Johannessen D.C., Ekse D., Adlercreutz H. Influence of plasma oestrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Br. Cancer Res. Treat. 39:1996;335-341.
65. The Arinimdex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial in post-menopausal (PM) women. http://www.breastcancerupdate.com.
66. Holmberg L., Norden T., Lindgren A., Wide L., Degerman M., Adami H.O. Pre-operative oestradiol levels - relation to survival in breast cancer. Eur. J. Surg. Oncol. 27:2000;152-156.
67. Fallowfield L., Leaity S.K., Howell A., Benson S., Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res. Treat. 55:1999;189-199.
68. Col N.F., Kirota L.K., Orr R.K., Erban J.K., Wong J.B., Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J. Clin. Oncol. 19:2001;2357-2363.
69. O'Meara E.S., Rossing M.A., Daling J.R., Elmore J.G., Barlow W.E., Weiss N.S. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst. 93:2001;754-762.
70. Hug V., Clark J., Johnson D. The results of modified use of chemotherapy for patients with metastatic breast cancer. Eur. J. Cancer. 30A:1994;438-442.
71. Horn Y., Walach N., Pavlotsky A., Barak F., Benz C. Randomised study comparing chemotherapy with and without estrogen priming in advanced breast cancer. Int. J. Oncol. 4:1994;499-501.
72. Marsden J., Sacks N.P.M., Baum M., A'Hern R.P., Whitehead M.I. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fertil. Steril. 73:2000;292-299.
73. Santen R., Jeng M.H., Wang J.P., Song R., Masamura S., McPherson R., Santner S., Yue W., Shim W.S. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J. Steroid Biochem. Mol. Biol. 79:2001;115-125.
74. Lønning P.E. Stepwise estrogen suppression manipulating the estrostat. J. Steroid Biochem. Mol. Biol. 70:2001;127-132.
75. Yue W., Berstein L.M., Wang J.P., Clark G.M., Hamilton C.J., Demers L.M., Santen R.J. The potential role of estrogen in aromatase regulation in the breast. J. Steroid Biochem. Mol. Biol. 79:2001;157-164.